» Articles » PMID: 38893662

Autoimmune Diseases and Plasma Cells Dyscrasias: Pathogenetic, Molecular and Prognostic Correlations

Overview
Specialty Radiology
Date 2024 Jun 19
PMID 38893662
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple myeloma and monoclonal gammopathy of undetermined significance are plasma cell dyscrasias characterized by monoclonal proliferation of pathological plasma cells with uncontrolled production of immunoglobulins. Autoimmune pathologies are conditions in which T and B lymphocytes develop a tendency to activate towards self-antigens in the absence of exogenous triggers. The aim of our review is to show the possible correlations between the two pathological aspects. Molecular studies have shown how different cytokines that either cause inflammation or control the immune system play a part in the growth of immunotolerance conditions that make it easier for the development of neoplastic malignancies. Uncontrolled immune activation resulting in chronic inflammation is also known to be at the basis of the evolution toward neoplastic pathologies, as well as multiple myeloma. Another point is the impact that myeloma-specific therapies have on the course of concomitant autoimmune diseases. Indeed, cases have been observed of patients suffering from multiple myeloma treated with daratumumab and bortezomib who also benefited from their autoimmune condition or patients under treatment with immunomodulators in which there has been an arising or worsening of autoimmunity conditions. The role of bone marrow transplantation in the course of concomitant autoimmune diseases remains under analysis.

References
1.
Bartosinska J, Purkot J, Karczmarczyk A, Chojnacki M, Zaleska J, Wlasiuk P . Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma. Cells. 2021; 10(2). PMC: 7920433. DOI: 10.3390/cells10020411. View

2.
Kaneko H, Endo T, Saitoh H, Katsuta Y, Aramaki T, Hayakawa H . Primary biliary cirrhosis associated with multiple myeloma. Intern Med. 1993; 32(10):802-5. DOI: 10.2169/internalmedicine.32.802. View

3.
Bommarito D, Hall C, Taams L, Corrigall V . Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. Clin Exp Immunol. 2017; 188(3):455-466. PMC: 5422858. DOI: 10.1111/cei.12949. View

4.
Allegra A, Casciaro M, Barone P, Musolino C, Gangemi S . Epigenetic Crosstalk between Malignant Plasma Cells and the Tumour Microenvironment in Multiple Myeloma. Cancers (Basel). 2022; 14(11). PMC: 9179362. DOI: 10.3390/cancers14112597. View

5.
de Weers M, Tai Y, van der Veer M, Bakker J, Vink T, Jacobs D . Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2010; 186(3):1840-8. DOI: 10.4049/jimmunol.1003032. View